THAR

Tharimmune, Inc. (NASDAQ:THAR) is a clinical-stage biotechnology company founded in 2017 and headquartered in Bridgewater, New Jersey. The company was originally incorporated as Hillstream BioPharma, Inc. before changing its name to Tharimmune in September 2023. Since going public in January 2022, Tharimmune has focused on developing therapeutic candidates targeting rare diseases, inflammatory conditions, and various forms of cancer. The company operates in the highly specialized and capital-intensive biotechnology sector, where drug development timelines typically span many years and require substantial investment before generating any revenue.